Following a limited submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Buprenorphine / naloxone (Suboxone®) sublingual film is recommended as an option for restricted use within NHS Wales as substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Suboxone® is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction. In accordance with NICE guidance such treatment should be considered in patients who are unsuitable for maintenance treatment with methadone. |
|||
|
|||
Medicine details |
|||
| Medicine name | buprenorphine/naloxone (Suboxone®) | ||
| Formulation | 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, 12 mg/3 mg sublingual film | ||
| Reference number | 4590 | ||
| Indication | Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Suboxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction |
||
| Company | Indivior UK Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Limited | ||
| Status | Recommended with restrictions | ||
| Advice number | 0621 | ||
| NMG meeting date | 03/03/2021 | ||
| AWMSG meeting date | 20/04/2021 | ||
| Date of issue | 28/04/2021 | ||
| Further information Indivior will discontinue supply of this product on 2nd March 2023. |
|||